Santiago Osorio

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Tiziano Barbui, Alessandro M. Vannucchi, Alberto Álvarez‐Larrán et al. · Leukemia · 2021 · 82 citations · Full text

Medicine, Hematology, Pharmacology +15

Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia.

Juan Luis Steegmann, Gemma Moreno, Concepción Aláez et al. · PubMed · 2003 · 49 citations

Medicine, Hematology, Immunology +17

Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients

Juan Carlos Hernández‐Boluda, Arturo Pereira, Irene Pastor‐Galán et al. · Blood Cancer Journal · 2018 · 46 citations · Full text

Medicine, Hematology, Oncology +14

Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response

Santiago Osorio, A. Durán, Juan Luis Steegmann · American Journal of Hematology · 2006 · 45 citations

Medicine, Pharmacology, Pharmacotherapy +12

Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.

Francisco Cervantes, Juan Carlos Hernández‐Boluda, J. L. Steegmann et al. · PubMed · 2003 · 43 citations

Pharmacy, Hematology, Pharmacotherapy +13